Based on its Affinity Detection by Mass Spectroscopy (ADMS) platform, Keythera Biopharmaceuticals develops a drug pipeline centered on first-in-class therapeutics, targeting major disease areas with urgent unmet clinical needs. The company's current R&D achievements comprise six novel drug candidates: two currently in Phase I clinical trials, one in Phase II, one progressing through Investigational New Drug (IND) application, and two at the Preclinical Candidate Compound (PCC) proof-of-concept stage.

Keythera Biopharmaceuticals specializes in utilizing an advanced screening platform called Affinity Detection by Mass Spectroscopy (ADMS), which is based on affinity-based high throughput screening technology. This cutting-edge platform allows for the screening of up to 250,000 compounds per day on each ADMS workstation. ADMS integrates various technologies, including bioinformatics, chemical informatics, structural chemistry, computer-aided drug design, and combinatorial chemistry.

By serving as an intelligent platform for drug screening and optimization, ADMS significantly expedites the discovery of innovative small molecule drugs while mitigating the risks associated with new drug development. It plays a crucial role in the development of new drugs with clinical differentiation. One key advantage of ADMS is its incorporation of artificial intelligence, which overcomes the limitations of other AI-assisted drug development technologies by enabling rapid validation through the acquisition of experimental data.